Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer

International Journal of Urology

Volumn 13, Issue 7, 2006, Pages 915-919

  Kato, Tomonori ^a   Suzuki, Hiroyoshi ^a   Komiya, Akira ^a   Imamoto, Takashi ^a   Naya, Yukio ^a   Tobe, Toyofusa ^a   Ichikawa, Tomohiko ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Non palpable prostate cancer; Prostate biopsy; Retrospective study; Serum C reactive protein; Urinary white blood cell count

Indexed keywords

C REACTIVE PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN BLOOD LEVEL; PYURIA; RELIABILITY; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; C-REACTIVE PROTEIN; DIAGNOSIS, DIFFERENTIAL; ENDOSONOGRAPHY; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PALPATION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; URINE;

EID: 33745916418     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01440.x     Document Type: Article

References (16)

1. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004; 101: 894-904.
2. Gisela C, Robot MJ, Schrader FH. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int. 2005; 95: 231-7.
3. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 1991; 145: 907-23.
4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 1987; 317: 909-16.
5. Morote J, Lopez M, Encabo G, de Torres IM. Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. Eur. Urol. 2000; 37: 537-40.
6. Catalona WJ, Southwick PC, Slawin KM et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56: 255-60.
7. Brawer MK, Cheli CD, Neaman IE et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J. Urol. 2000; 163: 1476-80.
8. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; 282: 236-7.
9. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest. Urol. 1979; 17: 159-63.
10. Suzuki H, Akakura K, Igarashi T et al. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. J. Urol. 2004; 171: 182-6.
11. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF) -I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-53.
12. Hersh MR, Knapp EL, Choi J. Newer imaging modalities to assess tumor in the prostate. Cancer Control 2004; 11: 353-7.
13. Inahara M, Suzuki H, Nakamachi H et al. Clinical evaluation of transrectal power doppler imaging in the detection of prostate cancer. Int. Urol. Nephrol. 2004; 36: 175-80.
14. Stancik I, Luftenegger W, Klimpfinger M, Muller MM, Hoeltl W. Effect of NIH-IV prostatitis on free and free-to-total PSA. Eur. Urol. 2004; 46: 760-4.
15. Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J. Urol. 1997; 157: 1301-3.
16. Karazanashvili G, Managadze L. Prostate-specific antigen (PSA) value change after antibacterial therapy of prostate inflammation, as a diagnostic method for prostate cancer screening in cases of PSA value within 4-10 ng/mL and nonsuspicious results of digital rectal examination. Eur. Urol. 2001; 39: 538-43.